I believe this case deserves greater clarity in the public interest not because the drug is more important than other drugs or that a rejection followed by an approval is inherently unusual. The drug, Tudriqev, developed by Replimune for advanced melanoma, deserves attention because the Food and Drug Administration rejected it twice. Representatives of Replimune then met …
Continue reading “A Melanoma Drug Went From Two Rejections to Approval. The FDA’s Reason Should Be Easier to Find.”
The post A Melanoma Drug Went From Two Rejections to Approval. The FDA’s Reason Should Be Easier to Find. appeared first on The Well News | Pragmatic, Governance, Fiscally Responsible, News & Analysis. Read More
